Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
TECHNOLOGY
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
INVESTING
Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment
By Tom Bemis
Jan 27, 2020 5:37 PM EST
PRESS RELEASES
Nektar Appoints Dr. Brian Kotzin As Interim Chief Medical Officer And Head Of Development
By PR Newswire
Jan 5, 2021 4:20 PM EST
PRESS RELEASES
Nektar Therapeutics Announces Agreement With Healthcare Royalty To Sell ADYNOVATE® And MOVANTIK® Royalties For $150 Million
By PR Newswire
Dec 22, 2020 8:30 AM EST
PRESS RELEASES
Nektar Therapeutics Announces Dosing Of First Patients In Phase 1/2 Study Of Its IL-15 Agonist, NKTR-255, In Combination With Cetuximab In Patients With Head And Neck Squamous Cell Carcinoma Or Colorectal Cancer
By PR Newswire
Dec 15, 2020 8:30 AM EST
PRESS RELEASES
Nektar Therapeutics Announces Presentation Of Preclinical Data For NKTR-255, Its Novel IL-15 Agonist, At The American Society Of Hematology (ASH) 2020 Annual Meeting
By PR Newswire
Dec 7, 2020 4:00 PM EST
PRESS RELEASES
New Clinical Data Presented From Phase 1b Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At 2020 American College Of Rheumatology (ACR) Congress
By PR Newswire
Nov 4, 2020 10:15 AM EST
PRESS RELEASES
Nektar Therapeutics To Host Webcast Conference Call For Analysts & Investors For 2020 American College Of Rheumatology (ACR) Congress
By PR Newswire
Oct 29, 2020 6:00 PM EDT
PRESS RELEASES
Nektar To Announce Financial Results For The Third Quarter 2020 On Thursday, November 5, 2020, After Close Of U.S.-Based Financial Markets
By PR Newswire
Oct 28, 2020 6:00 PM EDT
PRESS RELEASES
Nektar To Announce Financial Results For The Second Quarter 2020 On Thursday, August 6, 2020, After Close Of U.S.-Based Financial Markets
By PR Newswire
Jul 28, 2020 6:00 PM EDT
PRESS RELEASES
Data Presented From Phase 1b Study Of NKTR-358, A Novel T Regulatory Cell Stimulator, At Annual European Congress Of Rheumatology (EULAR 2020)
By PR Newswire
Jun 4, 2020 5:00 PM EDT
PRESS RELEASES
Nektar Therapeutics To Host Webcast Conference Call For Analysts & Investors During 2020 Virtual European Congress Of Rheumatology (EULAR 2020)
By PR Newswire
May 29, 2020 5:00 PM EDT
PRESS RELEASES
Nektar Therapeutics Announces Publication Of Results From Phase 1 Dose-Escalation Study For Bempegaldesleukin Plus Nivolumab In 'Cancer Discovery' Journal
By PR Newswire
May 22, 2020 8:30 AM EDT
PRESS RELEASES
Nektar To Announce Financial Results For The First Quarter 2020 On Thursday, May 7, 2020, After Close Of U.S.-Based Financial Markets
By PR Newswire
Apr 28, 2020 5:00 PM EDT
PRESS RELEASES
Nektar Therapeutics To Webcast Presentation At The Cowen And Company 40th Annual Health Care Conference
By PR Newswire
Feb 28, 2020 6:30 PM EST
PRESS RELEASES
Nektar To Announce Financial Results For The Fourth Quarter And Year-Ended 2019 On Thursday, February 27, 2020, After Close Of U.S.-Based Financial Markets
By PR Newswire
Feb 18, 2020 5:00 PM EST
PRESS RELEASES
Nektar Therapeutics Announces Publication Of Two Manuscripts On Lead Immuno-oncology Candidate, Bempegaldesleukin (Bempeg) In Nature Communications
By PR Newswire
Feb 3, 2020 8:00 AM EST
INVESTING
Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment
By Tom Bemis
Jan 27, 2020 5:37 PM EST
PRESS RELEASES
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Nektar Therapeutics - NKTR
By PR Newswire
Jan 24, 2020 7:02 PM EST
Video
Nektar Still Has Some Juice
Jan 15, 2020 10:03 AM EST
INVESTING
Nektar Squeezed as FDA Rejects Opioid Addiction-Fighting Drug
By M. Corey Goldman
Jan 15, 2020 9:44 AM EST
PRESS RELEASES
Nektar Issues Statement Regarding FDA Advisory Committee Vote For Oxycodegol
By PR Newswire
Jan 14, 2020 10:47 PM EST
PRESS RELEASES
Shareholder Alert: Robbins LLP Reminds Investors Nektar Therapeutics (NKTR) Sued For Misleading Shareholders
By Business Wire
Jan 10, 2020 2:32 PM EST
INVESTING
Nektar Therapeutics, Bristol-Myers Expand Effort to Develop Treatment for Cancer
By Dan Weil
Jan 10, 2020 1:01 PM EST
PRESS RELEASES
Nektar Therapeutics' President And CEO, Howard Robin, To Present At The 38th Annual J.P. Morgan Healthcare Conference In San Francisco, CA
By PR Newswire
Jan 7, 2020 9:00 AM EST
INVESTING
Nektar Shares Drop After Double Downgrade to Sell at Goldman Sachs
By M. Corey Goldman
Oct 8, 2019 5:12 PM EDT